DNA hypermethylation in breast cancer and its association with clinicopathological features

Cancer Letters

Volumn 237, Issue 2, 2006, Pages 272-280

  Li, ShaoYing ^a   Rong, Minna ^a   Iacopetta, Barry ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Breast cancer; Histological grade; Methylation; Tumour suppressor gene

Indexed keywords

BRCA1 PROTEIN; CYCLIN D2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROTEIN P16; PROTEIN P53; RETINOIC ACID RECEPTOR BETA; TRANSCRIPTION FACTOR TWIST; UVOMORULIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DNA METHYLATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); RECEPTORS, ESTROGEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33646949481     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.06.011     Document Type: Article

References (44)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94 (2001) 153-156
2. Herman J.G., and Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349 (2003) 2042-2054
3. Yang X., Yan L., and Davidson N.E. DNA methylation in breast cancer. Endocr. Relat. Cancer 8 (2001) 115-127
4. Szyf M., Pakneshan P., and Rabbani S.A. DNA methylation and breast cancer. Biochem. Pharmacol. 68 (2004) 1187-1197
5. Toyota M., Ahuja N., Ohe-Toyota M., Herman J.G., Baylin S.B., and Issa J.P. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96 (1999) 8681-8686
6. Hawkins N., Norrie M., Cheong K., Mokany E., Ku S.L., Meagher A., et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 122 (2002) 1376-1387
7. van Rijnsoever M., Grieu F., Elsaleh H., Joseph D., and Iacopetta B. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 51 (2002) 797-802
8. Yamashita K., Dai T., Dai Y., Yamamoto F., and Perucho M. Genetics supersedes epigenetics in colon cancer phenotype. Cancer Cell 4 (2003) 121-131
9. Anbazhagan R., Fujii H., and Gabrielson E. Microsatellite instability is uncommon in breast cancer. Clin. Cancer Res. 5 (1999) 839-844
10. Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L., Markowitz S., et al. Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers. Oncogene 20 (2001) 1005-1009
11. Adem C., Soderberg C.L., Cunningham J.M., Reynolds C., Sebo T.J., Thibodeau S.N., et al. Microsatellite instability in hereditary and sporadic breast cancers. Int. J. Cancer 107 (2003) 580-582
12. Yan P.S., Perry M.R., Laux D.E., Asare A.L., Caldwell C.W., and Huang T.H. CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer. Clin. Cancer Res. 6 (2000) 1432-1438
13. Garcia J.M., Silva J., Pena C., Garcia V., Rodriguez R., Cruz M.A., et al. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 41 (2004) 117-124
14. Fackler M.J., McVeigh M., Evron E., Garrett E., Mehrotra J., Polyak K., et al. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma. Int. J. Cancer 107 (2003) 970-975
15. Lehmann U., Langer F., Feist H., Glockner S., Hasemeier B., and Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am. J. Pathol. 160 (2002) 605-612
16. Widschwendter M., Siegmund K.D., Muller H.M., Fiegl H., Marth C., Muller-Holzner E., et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. 64 (2004) 3807-3813
17. Bae Y.K., Brown A., Garrett E., Bornman D., Fackler M.J., Sukumar S., et al. Hypermethylation in histologically distinct classes of breast cancer. Clin. Cancer Res. 10 (2004) 5998-6005
18. Soong R., Iacopetta B.J., Harvey J.M., Sterrett G.F., Dawkins H.J., Hahnel R., and Robbins P.D. Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. Int. J. Cancer 74 (1997) 642-647
19. Bianco T., Chenevix-Trench G., Walsh D.C., Cooper J.E., and Dobrovic A. Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis 21 (2000) 147-151
20. Catteau A., Harris W.H., Xu C.F., and Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18 (1999) 1957-1965
21. Chen C.M., Chen H.L., Hsiau T.H., Hsiau A.H., Shi H., Brock G.J., et al. Methylation target array for rapid analysis of CpG island hypermethylation in multiple tissue genomes. Am. J. Pathol. 163 (2003) 37-45
22. Esteller M., Silva J.M., Dominguez G., Bonilla F., Matias-Guiu X., Lerma E., et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumours. J. Natl Cancer Inst. 92 (2000) 564-569
23. Evron E., Dooley W.C., Umbricht C.B., Rosenthal D., Sacchi N., Gabrielson E., et al. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 357 (2001) 1335-1336
24. Evron E., Umbricht C.B., Korz D., Raman V., Loeb D.M., and Niranjan B. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res. 61 (2001) 2782-2787
25. Fackler M.J., McVeigh M., Mehrotra J., Blum M.A., Lange J., Lapides A., et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res. 64 (2004) 4442-4452
26. Hu X.C., Wong I.H., and Chow L.W. Tumour-derived aberrant methylation in plasma of invasive ductal breast cancer patients: clinical implication. Oncol. Rep. 10 (2003) 1811-1815
27. Hu X.C., Loo W.T., and Chow L.W. E-cadherin promoter methylation can regulate its expression in invasive ductal breast cancer tissue in Chinese woman. Life Sci. 71 (2002) 1397-1404
28. Hui R., Macmillan R.D., Kenny F.S., Musgrove E.A., Blamey R.W., Nicholson R.I., et al. INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin. Cancer Res. 6 (2000) 2777-2787
29. Mehrotra J., Ganpat M.M., Kanaan Y., Fackler M.J., McVeigh M., Lahti-Domenici J., et al. Estrogen receptor/progesterone receptor-negative breast cancers of young African-American women have a higher frequency of methylation of multiple genes than those of Caucasian women. Clin. Cancer Res. 10 (2004) 2052-2057
30. Mehrotra J., Vali M.M., McVeigh M., Kominsky S.L., Fackler M.J., Lahti-Domenici J., et al. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin. Cancer Res. 10 (2004) 3104-3109
31. Nielsen N.H., Roos G., Emdin S.O., and Landberg G. Methylation of the p16 (Ink4a) tumour suppressor gene 5′-CpG island in breast cancer. Cancer Lett. 163 (2001) 59-69
32. Parrella P., Poeta M.L., Gallo A.P., Prencipe M., Scintu M., Apicella A., et al. Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumour. Clin. Cancer Res. 10 (2004) 5349-5354
33. Pu R.T., Laitala L.E., Alli P.M., Fackler M.J., Sukumar S., and Clark D.P. Methylation profiling of benign and malignant breast lesions and its application to cytopathology. Mod. Pathol. 16 (2003) 1095-1101
34. Rice J.C., Ozcelik H., Maxeiner P., Andrulis I., and Futscher B.W. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 21 (2000) 1761-1765
35. Widschwendter M., Berger J., Hermann M., Muller H.M., Amberger A., Zeschnigk M., et al. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J. Natl Cancer Inst. 29 (2000) 826-832
36. Yan L., Yang X., and Davidson N.E. Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. J. Mammary Gland Biol. Neoplasia 6 (2001) 183-192
37. Zhu K., Davidson N.E., Hunter S., Yang X., Payne-Wilks K., Roland C.L., et al. Methyl-group dietary intake and risk of breast cancer among African-American women: a case-control study by methylation status of the estrogen receptor alpha genes. Cancer Causes Control 14 (2003) 827-836
38. Nass S.J., Herman J.G., Gabrielson E., Iversen P.W., Parl F.F., Davidson N.E., and Graff J.R. Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer. Cancer Res. 60 (2000) 4346-4348
39. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93 (1996) 9821-9826
40. Paulin R., Grigg G., Davey M.W., and Piper A.A. Urea improves efficiency of bisulphate-mediated sequencing of 5′-methylcytosine in genomic DNA. Nucleic Acids Res. 26 (1998) 5009-5010
41. Toyota M., Ohe-Toyota M., Ahuja N., and Issa J.P. Distinct genetic profiles in colorectal tumours with or without the CpG island methylator phenotype. Proc. Natl Acad. Sci. USA 97 (2000) 710-715
42. Sathyanarayana U.G., Padar A., Huang C.X., Suzuki M., Shigematsu H., Bekele B.N., and Gazdar A.F. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma. Clin. Cancer Res. 9 (2003) 6389-6394
43. Ward R.L., Cheong K., Ku S.L., Meagher A., O'Connor T., and Hawkins N.J. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J. Clin. Oncol. 21 (2003) 3729-3736
44. Van Rijnsoever M., Elsaleh H., Joseph D., McCaul K., and Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin. Cancer Res. 9 (2003) 2898-2903